INTRODUCTION
============

Myelin is an essential physiological structure, allowing for the rapid and effective transmission of neural signals. Impaired myelination, prevalent in disorders such as multiple sclerosis, severely hampers the ability of neurons to communicate, resulting in functional deficits and axonal degeneration ([@B79]; [@B45]; [@B15]). Factors involved in regulating myelination during development are often also involved in demyelinating disorders, and understanding their actions is crucial to designing treatments or therapies ([@B72]; [@B4]; [@B50]; [@B92]; [@B9]).

OLs (oligodendrocytes) are the myelinating cells of the CNS (central nervous system). OLs are generated through a series of specific developmental stages ([@B65]; [@B63]), during which they are exposed to a range of signalling factors that can be inductive or inhibitory, extracellular or intracellular ([@B55]). OPCs (OL precursor cells) originate in ventricular zones at E12.5 (embryonic day 12.5) in the rodent CNS and migrate dorsally and radially, expressing markers such as A2B5, NG2 and PDGFr-α (platelet-derived growth factor receptor α). Once differentiation begins, OPCs progress to immature OLs, generating processes and expressing GalC (galactocerebroside). After contacting neurons, OPCs begin to extend processes, express myelin proteins, including PLP (proteolipid protein), MBP (myelin basic protein) and CNP (2′,3′ cyclic nucleotide 3′-phosphodiesterase), then ensheathe axons in protein and lipid heavy myelin ([@B22]; [@B55]). While the signals that influence this development are beginning to be characterized, the extent of their interactions remains to be fully explored.

Initially, signals in the ventral spinal cord, especially Shh (sonic hedgehog), induce expression of transcription factors essential for OL specification and development, including Olig1 and Olig2 ([@B51]; [@B94]; [@B93]). In contrast, signals emanating from the roof plate in the dorsal spinal cord can inhibit this development ([@B83]), possibly to control the exact times when these cells reach and myelinate dorsal regions. There are, however, dorsal populations of OPCs whose generation is Shh independent, although their overall contributions appear to be limited and their distinct functions are unknown ([@B8]; [@B40]; [@B81]; [@B41]). Two families of dorsal signalling factors, the BMPs (bone morphogenic proteins) and the Wnts, have been shown to exert inhibitory effects on OPC differentiation.

BMPs are members of the TGFβ (transforming growth factor β) signalling family, and they have many roles in the developing nervous system involving embryonic patterning, cell proliferation, specification, differentiation and apoptosis ([@B48], [@B47]; [@B54]; [@B87]; [@B71] for review). Of the Wnt and BMP families, BMP has been more extensively investigated with regard to OL development, exerting time- and stage-specific effects. BMPs drastically inhibit OPC differentiation into mature OLs, instead promoting astrogliogenesis ([@B24]; [@B56]; [@B68]; [@B70]; [@B11]).

The Wnts are another family of dorsal-secreted factors involved in many of the same roles as BMPs in the nervous system, including embryonic patterning, cell specification, proliferation, migration and differentiation ([@B14]; [@B12]; [@B6]; [@B28]; [@B39]; [@B36]; [@B80] for review). Recent studies have investigated the influence of canonical Wnt signalling on OL development, both *in vitro* and *in vivo*, indicating that the Wnts and BMPs have similar effects. In spinal cord explants and OPC cultures, ectopic Wnt3a application inhibits the differentiation of OPCs into mature cells ([@B75]; [@B42]; [@B17]; [@B18]; [@B89]). Mutant mice in which Wnt signalling is constitutively activated in cells of OL lineage display an early developmental decrease in mature OLs. This effect diminishes as the mice age, however, suggesting that the importance of Wnt signalling may vary over the course of OL development ([@B17]; [@B18]).

The interaction of BMPs and Wnts is well documented in a variety of different systems, their expression is spatially and temporally similar, and they are functionally involved in many of the same processes. Their relationship, however, varies based on tissue and developmental timeline: depending on context, they can directly or indirectly be inductive, antagonistic or synergistic ([@B76]; [@B25]; [@B34] for review). There is evidence that Wnt signalling prevents oligodendroglial specification at the neural stem cell stage by up-regulating BMPs through neurogenesis ([@B40]), but how these two pathways may interact in OL development has not been explored in detail. An understanding of the interaction of these pathways is an important avenue for developing treatments and therapies for demyelinating events. It is well documented that BMPs are up-regulated in CNS injury and models of demyelinating disease ([@B72], [@B73]; [@B71]; [@B9]; [@B35]), and can play roles in preventing remyelination. In parallel, several recent studies have also found that members and effectors of the Wnt family are up-regulated in similar paradigms, and may have similar inhibitory effects on recovery ([@B50]; [@B17]; [@B59]; [@B85]).

Because Wnts and BMPs have similar sites of origin and effects on OLs during development and demyelinating events, we hypothesized that these two signalling factors mutually regulate OL development. To explore this interaction, we have employed effectors and antagonists of both canonical Wnt and BMP signalling on both mutant and normal OPC cultures. We find that while both BMP4 and Wnt3a inhibit the differentiation of OPCs, when the BMP pathway is blocked -- by either chemical or genetic means -- the effects of both Wnt3a and BMP4 are abrogated. In contrast, the effect of BMP4 on OPC differentiation is not altered when the canonical Wnt signalling pathway is blocked. Our results indicate that the BMP pathway is necessary for canonical Wnt signalling to inhibit OPC differentiation.

EXPERIMENTAL
============

Cell culture generation and treatment
-------------------------------------

All experiments were performed in accordance with the guidelines set forth by the Children\'s Hospital of Philadelphia Institutional Animal Care and Use Committee. To generate purified OPC cultures from newborn Sprague--Dawley rats or mixed background mice, forebrain cells were harvested and seeded on 100 mm Petri dishes in serum containing medium as previously described ([@B70]; [@B18]). After 24 h, cultures were switched to serum-free growth medium containing Neurobasal medium (Invitrogen) with B27 supplement (1:50 Life technologies), 10 ng/ml basic fibroblast growth factor (R & D Systems, Minneapolis, MN, U.S.A.), 2 ng/ml platelet-derived growth factor (R & D), and 1 ng/ml neurotrophin-3 (Peprotech, Rocky Hill, NJ, U.S.A.).

Rat cultures were purified 6--8 days after plating by immunopanning as previously described ([@B24]). Cells were successively seeded on to two sets of dishes coated with Ran-2 antibody to bind type-1 astrocytes, meningeal cells and microglia. Cells were then put on dishes plated with A2B5 antibody (undiluted, hybridoma supernatant, ATCC, Rockville, MD, U.S.A.; [@B16]) to bind the OPCs. When cells reached confluency, they were sub-cultured in polylysine-coated flasks, 12 mm polylysine-coated coverslips, 100 mm polylysine-coated Petri dishes or 50 mm polylysine-coated Petri dishes. Cells could be passaged 3--4 times. Cultures were considered purified if they contained fewer than 5% astrocytes.

To culture mouse OPCs, cells were harvested from the forebrains of individual animals using the same methods and media as previously described. Individual mouse brains were cultured singularly until genotypes were identified by PCR of tail DNA. At this stage, identically genotyped cultures were combined. OPCs were purified using a gentle modified washdown procedure as previously described ([@B18]). Briefly, 4 ml of Hanks-buffered salt solution without Mg^+^ and Ca^+^ was drawn into a Pasteur pipette, and then forcefully released on the cell monolayer at an angle. OPCs would detach, leaving any astrocytes adherent to the plate. OPCs and the Hanks medium were then drawn up into the pipette and the procedure could be repeated several times until enough cells were collected. The detached OPCs were collected in Hanks medium, triturated several times with the Pasteur pipette and centrifuged at 100 ***g*** for 5 min. The pellet was then plated on to a polylysine-coated flask. Cultures were considered purified if they contained fewer than 5% astrocytes.

When OPCs were differentiated into mature OLs, growth medium was removed, and cell cultures were fed with DM (differentiation medium), consisting of 50% DMEM (Dulbecco\'s modified Eagle\'s medium) and 50% Ham\'s F12, with 50 μg/ml transferrin, 5 μg/ml putresine, 3 ng/ml progesterone, 2.5 ng/ml selenium, 12.5 μg/ml insulin, 0.4 μg/ml T4, 0.3% glucose, 2 mM glutamine and 10 ng/ml biotin. Cells were allowed to differentiate for 3 days to examine markers of immature OLs or 5 days to look at markers of mature OLs. Treatment conditions involved the application of signalling factors to some cultures; these were 50 ng/ml Wnt3a (R & D), 50 or 10 ng/ml BMP4 (R & D), 100 ng/ml Dkk-1 (Dikkopf-1) (R & D) and 500 ng/ml Noggin (R & D).

Immunofluorescence
------------------

Immunostaining and preparation of coverslip-plated cells were performed as previously described ([@B23]; [@B18]). Antibody pairs used to detect surface antibodies were anti-A2B5 with goat anti-mouse IgM and anti-galactocerebroside (RmAb GalC, undiluted, hybridoma supernatant; [@B67]) with goat-anti-mouse IgG3. The antibody pairs used to detect internal antibodies were GFAP (glial fibrillary acidic protein) and Olig2. Anti-GFAP (undiluted, hybridoma supernatant, gift of Dr Virginia Lee, University of Pennsylvania) was paired with goat anti-rat IgG. To label Olig2 (1:500, Millipore, paired with goat anti-rabbit IgG), cells were blocked for 10 min in 0.3% Triton X-100 after fixing with 4% (w/v) paraformaldehyde. To label TCF4 (TCF7L2, 1:100, Millipore, paired with goat anti-mouse IgG; [@B89]), cells were fixed with 4% paraformaldehyde and blocked for 30 min in block containing 0.1% Triton X-100, 2% BSA and 20% FCS (fetal calf serum). For all cell counts, positively labelled cells and DAPI+ (4\', 6-diamidino-2-phenylindole) cells were counted in ten fields in each of two coverslips from each of at least three separate *in vitro* preparations, using a Leica DM6000B fluorescence microscope at ×63 magnification. Approx. 3000 cells were counted per experimental data point (1000 cells per condition per *n*).

Western-blot analysis
---------------------

Rat cells were collected for Western-blot analysis as previously described ([@B18]). Cells were treated with 50 ng/ml BMP4 or Wnt3a and collected after 30 min, 3 or 48 h. Membranes were incubated with BMP4 antibody (1:500, R & D), HRP (horseradish peroxidase)-conjugated anti-mouse IgG secondary antibody (1:1000), or with Phosphorylated-Smad (1:3000, Cell Signaling) followed by HRP-conjugated anti-rat IgG secondary antibody (1:1000) and imaged using ECL® reagents (Amersham, Piscataway, NJ, U.S.A.) and hyperfilm (Amersham). Blots were stripped and reprobed with GAPDH (glyceraldehyde-3-phosphate dehydrogenase; 1:2,500, Chemicon International) as a loading control for protein quantification. Secondary antibodies were purchased from Jackson Laboratories.

Generation of mutant mice
-------------------------

The *Bmpr1 DKO* (*BMPR1* double-knockout) mice were generated as previously described ([@B87]; [@B69]). Lines include a classical BMPr1a KO ([@B57]), a BMPR1a conditional KO mouse ([@B1]; [@B58]), a BMPR1b classical KO mouse (gift from Dr Karen Lyons, UCLA; [@B90]) and a *Bcre-32* transgenic mouse. The generation of these mice has been previously described ([@B87]; [@B69]). Normal littermates have one functional allele of both BMPR1 receptors and do not exhibit any phenotype. All mice were killed at P1 and OPC cultures were successfully harvested. *β-Cat-null* (β-catenin loss-of-function mutant) mice were made available by crossing β-catenin^floxedexon3−6/floxedexon3−6^ mice (made available by Dr Walter Birchmeier, Max Delbruck Centrum, Germany) with *Cnp-Cre* mice, obtained from Dr Klaus Nave, Max Planck Institute, Germany. Generation of β-catenin^floxedexon3−6/floxedexon3−6^ mice has been described previously ([@B31]), as has the generation of *Cnp-Cre* mice ([@B45]). Offspring were established by mating β-catenin^floxedexon3−6/floxedexon3−6^; +/+ mice with β-catenin^floxedexon3−6/+^; CNP/+ mice. β-catenin loss of function mice had the genotype β-catenin^floxedexon3−6/floxedexon3−6^; CNP/+.

Real-time PCR
-------------

OPC cultures were grown on 50 mm dishes and harvested at 6 or 48 h post-treatment with 50 ng/ml Wnt3a or 50 ng/ml BMP4, with or without 500 ng/ml Noggin. Cells were extracted with TRIzol® (Molecular Research Center, Cincinnati, OH, U.S.A.). cDNA was reverse transcribed from 2 to 5 μg RNA per treatment group using Superscript III First Strand Synthesis Kit for RT--PCR (reverse transcription--PCR; Invitrogen no. 18080044). Primers used were GAPDH, MBP and ID2 (IDT Technologies). QPCR was performed using SYBR Green (Applied Biosystems) with the MXPro 3000P. Quantification was determined using the SYBR Green with the Dissociation Curve method, as per the protocol of the manufacturer. Threshold values of fluorescence, *C*~t~ values, were calculated at least three times per cycle, and values relative to control conditions were used to determine treatment differences. Samples were measured in triplicate for each experiment.

Image acquisition
-----------------

All images were acquired using a Leica DM6000B fluorescence microscope. All images were mounted using Vectashield (Vector). Images were acquired with a Leica DFC360 Fx camera, using Leica Application Suite 2.1.0 software. Images were evenly enhanced using Adobe Photoshop (Adobe Systems, Mountain View, CA, U.S.A.).

RESULTS
=======

Wnt and BMP inhibit OL differentiation
--------------------------------------

To observe the effects of Wnt and BMP on OL development *in vitro*, we established primary cultures of OPCs from mouse or rat brain and purified them to remove astrocytes and other non-OL lineage cells. Cells were grown to confluency on coverslips or dishes, subsequently growth factors were removed and DM was added with or without BMP4 (50 ng/ml) or Wnt3a (50 ng/ml). We selected BMP4 because, of all the BMP signalling effectors, it is the most intimately involved and most abundant during OL development ([@B3]). We chose 50 ng/ml BMP4 because it had the maximal effect in our previous studies ([@B24]; [@B70]). We selected Wnt3a as an effector of canonical Wnt signalling based on its location in developing dorsal spinal cord and its effects on OPCs from previous studies ([@B75]; [@B18]). A dose−response curve showed that 50 ng/ml Wnt3a most effectively inhibited OPCs from differentiating (K. Feigenson and J.B. Grinspan, results not shown). After 3 days in DM, the treated samples were processed for IHC (immunohistochemistry), and labelled with antibodies directed against GalC, a marker of early differentiation, and A2B5, which labels OPCs. In control conditions, 26% of rat cells expressed GalC, and 67% were labelled with A2B5, as observed in previous studies ([@B18]). The overlap in labelling between A2B5 and GalC is temporary and the A2B5 labelling will slowly disappear as the OLs mature ([@B13]; [@B18]). In contrast, GalC labelling was almost completely absent in BMP4 treatment conditions, while A2B5 labelling was unchanged. Wnt3a treatment reduced GalC labelling by 33% (*P*\<0.05), in keeping with the 30--40% decrease we have observed previously, and also did not significantly affect the amount of cells being labelled with A2B5 or alter their morphology ([Figures 1A and 1C](#F1){ref-type="fig"}).

![BMP4 and Wnt3a treatment inhibit OL differentiation\
Cultures of rat OPCs were grown to confluence, switched to DM, alone or with BMP4 or Wnt3a, and then immunostained for GalC, GFAP and A2B5. (**A**) After 3 days in DM, many control OPCs expressed GalC and A2B5. BMP4-treated OPCs expressed A2B5 at comparable levels to controls conditions, but almost no cells expressed GalC (*P*\<0.01). Wnt3a-treated cells had comparable levels of A2B5 expressing cells relative to control conditions, but a 33% reduction in the number of cells expressing GalC (*P*\<0.05). (**B**) Control cultures had occasional labelling of GFAP+ cells, whereas 6.5 times as many cells in the BMP4 treatment condition were positively labelled with GFAP antibody (*P*\<0.01). Wnt3a treatment did not noticeably change the number of GFAP+ cells relative to control conditions. (**C**, **D**) Bar graphs quantify the number of cells labelled with specific antibodies, measured relative to control conditions, *n* = 9. Images shown were taken at ×20 magnification.](an003e061f01){#F1}

To observe the effects of BMP4 and Wnt3a on the number of astrocytes in culture, we also immunolabelled cells with antibodies directed against GFAP. Control cultures and cultures treated with Wnt3a contained fewer than 5% astrocytes, while in BMP4-treated cultures the number of astrocytes increased 6.5-fold (*P*\<0.05, [Figures 1B and 1D](#F1){ref-type="fig"}). We have previously shown that neither signalling factor had any significant impact on the amount of cells undergoing apoptosis, proliferation or differentiation into neurons ([@B24]; [@B18]). These results indicate that BMP4 can completely inhibit OPC differentiation and induce astrogliogenesis, while Wnt3a can partially inhibit OPC differentiation without having an impact on astrocyte cell fate.

A BMP inhibitor blocks the effects of both BMP4 and Wnt3a signalling but a Wnt inhibitor blocks only Wnt3a signalling
---------------------------------------------------------------------------------------------------------------------

To determine whether there is a relationship between the Wnt and BMP signalling pathways, pharmacological inhibitors of canonical Wnt signalling were added concurrently with BMP4 and pharmacological inhibitors of BMP signalling were added concurrently with Wnt3a. Noggin (500 ng/ml), an inhibitor of canonical BMP signalling, was added to confluent cell cultures along with DM, 50 ng/ml BMP4 or 50 ng/ml Wnt3a. Noggin treatment alone did not alter the number of GalC+ cells relative to control conditions ([Figure 2A](#F2){ref-type="fig"}). Although OPCs secrete both BMP and noggin, the secreted noggin normally limits the endogenous effects of BMP ([@B43a]). Noggin added with BMP4 completely blocked the effect of BMP4 and the number of GalC+ cells was not significantly different from the untreated control condition ([Figure 2A](#F2){ref-type="fig"}). Similarly, when noggin was added along with Wnt3a, the number of GalC+ cells was the same as in the untreated control condition, indicating that blocking the BMP signalling pathway blocks the inhibitory actions of BMP4 and Wnt3a on OPC differentiation *in vitro* ([Figure 2A](#F2){ref-type="fig"}).

![Pharmacological inhibition of the BMP pathway blocks the effects of Wnt3a and BMP4 on OL differentiation\
OPC cultures were placed in DM for 3 days, alone or with BMP4 or Wnt3. Noggin or DKK-1 was added to similarly treated cells. (**A**) BMP4 treatment eliminated GalC expression (*P*\<0.01), but the addition of noggin concurrently with BMP4 rescued this effect. Similarly, Wnt3a treatment reduced the number of GalC+ cells by 39% relative to controls (*P*\<0.05), but concurrent noggin treatment rescued this effect (*n* = 7). (**B**) Dkk-1 addition abrogated the effect of Wnt3a on the number of GalC+ cells (*P*\<0.01), and did not alter the BMP4 mediated elimination of GalC expressing cells (*P*\<0.05, *n* = 3).](an003e061f02){#F2}

To determine whether blocking the canonical Wnt signalling pathway could block BMP signalling, we treated OPC cultures with Dkk-1, an inhibitor of canonical Wnt signalling. Dkk-1 treatment (100 ng/ml) alone did not alter the number of GalC+ cells relative to control conditions. When used concurrently with Wnt3a, however, Dkk-1 blocked the inhibitory effect of Wnt3a. In contrast, BMP4 completely inhibited GalC expression in cells even when treated concurrently with Dkk-1 ([Figure 2B](#F2){ref-type="fig"}), indicating that blocking the canonical Wnt signalling pathway does not block the BMP signalling pathway *in vitro*. These results suggest that BMP4 does not signal upstream of the canonical Wnt pathway, and that the BMP pathway is not dependent on the Wnt signalling pathway.

Genetic ablation of the BMP signalling pathway blocks the effects of BMP4 and Wnt3a
-----------------------------------------------------------------------------------

We next used a genetic model to help determine the relationship between BMP4 and Wnt3a and confirm our pharmacological results. We obtained *Bmpr1 DKO* mice in which both BMPR1A and BMPR1B have been functionally inactivated in the neural tube by E10.5 using the *Bcre-32* transgenic allele. These mice have been characterized previously ([@B87]; [@B69]). OPCs cultured from the animals are able to differentiate, do not translocate Smad (a downstream effector of BMP signalling) to the nucleus, and do not respond to BMP treatment ([@B69]). We generated cultures from these DKO (double-knockout) animals as well as from single KOs (knockouts; *Bmpr1b KO*, *Bmpr1a KO*) and normal littermates. We then treated these cultures with DM alone or DM containing BMP4 or Wnt3a.

BMP4 completely eliminated GalC expression in normal mouse OPC cultures after 3 days in DM, and Wnt3a reduced the number of GalC+ cells by 41%. The number of A2B5+ cells did not vary from control conditions, replicating our previous findings in control cultures. These results were further replicated in OPC cultures from *Bmpr1a KO* and *Bmpr1b KO* mice ([Figure 3A](#F3){ref-type="fig"}). In the *Bmpr1 DKO* OPC cultures that were untreated or treated with BMP4, the cells differentiated to the extent of the normal cells, as we have previously shown ([@B69]). This indicates that the OPCs from animals without BMP signalling are able to differentiate normally but do not respond to BMP4. Similarly, when the *Bmpr1 DKO* OPC cultures were treated with Wnt3a, the number of GalC+ cells was not significantly different from control conditions or *Bmpr1 DKO* cells treated with BMP4 ([Figure 3A](#F3){ref-type="fig"}). These results indicate that when the BMP signalling pathway is completely abrogated, the canonical Wnt signalling pathway is similarly prevented from exerting an inhibitory effect on OPC differentiation. Further, when either *Bmpr1a* or *Bmpr1b* is individually deleted, the other type I receptor can compensate to maintain the integrity of the BMP signalling pathway and allow it to influence OL development. Our combined pharmacological and genetic results suggest that we can successfully block the effects of Wnt3a on OL differentiation by abrogating the BMP signalling pathway via two independent methods.

![OPCs from mice lacking the BMP type I receptor do not respond to BMP4 or Wnt3a treatment\
OPC cultures were generated from *Bmpr1 DKO*, *Bmpr1a KO*, *Bmpr1b KO*, and normal mice, grown, and placed in DM. (**A**) Three days after DM treatment, OPCs from all three types of mutant mice exhibited similar numbers of GalC+ cells relative to controls. BMP4 treatment almost completely eliminated GalC+ cells in *Bmpr1a KO*, *Bmpr1b KO*, and normal mouse OPCs (*P*\<0.01), but not in OPC cultures from *Bmpr1 DKO* mice. Similarly, Wnt3a expression decreased GalC+ cells in cultures from *Bmpr1a KO*, *Bmpr1b KO* and normal mice (*P*\<0.05), but not in those from *Bmpr1 DKO* mice. (**B**) OPC cultures generated from *β-Cat-null* mice and normal littermates were treated with BMP4 or Wnt3a. BMP4 almost completely reduced the number of GalC+ cells in both types of cultures (*P*\<0.01). Wnt3a reduced the number of GalC+ cells by 57% in control cultures, but this effect was not observed in the mutant cultures (*P*\<0.05, *n* = 3).](an003e061f03){#F3}

Genetic inhibition of the canonical Wnt signalling pathway blocks the effect of Wnt3a, but not that of BMP4, on OL differentiation
----------------------------------------------------------------------------------------------------------------------------------

To observe the effectiveness of canonical Wnt signalling and canonical BMP signalling on OL development when the Wnt signalling pathway has been effectively eliminated, we employed mutant mice with a conditional KO of the nuclear effector of canonical Wnt signalling, β-catenin \[*β-Cat-null* (β-catenin loss of function mutant mice)\]. Mice expressing a CNP-Cre transgene have been described previously ([@B45]; [@B18]). These mice are bred to a line of mice containing floxed sites surrounding exons 3--6 on the β-catenin gene ([@B31]). Upon Cre-mediated recombination, these exons are excised from the transcribed product and no functional β-catenin protein is produced. Wnt signalling is normally activated when β-catenin translocates to the nucleus, where it can activate TCF (T-cell factor)/LEF-1 (lymphoid enhancer factor-1) transcription factors. In these mutant mice, the Wnt signalling pathway is inhibited in all cells of OL lineage by preventing active β-catenin from being produced.

Mice were viable at P1 and OPC cultures were generated from mutants and normal littermates as previously described. Cultures were treated with DM with or without BMP4 or Wnt3a. Treatment with Wnt3a did not change the number of GalC+ cells relative to DM in the *β-Cat-null* OPC cultures, indicating that canonical Wnt signalling was effectively eliminated from OPCs ([Figure 3B](#F3){ref-type="fig"}). In contrast, BMP4 completely eliminated the expression of GalC in treated cells. These results indicate that blocking the canonical Wnt signalling pathway prevents the inhibitory effect of Wnt3a on OL development, but not that of BMP4, and that the BMP signalling pathway is not upstream of the Wnt signalling pathway or dependent on the Wnt signalling pathway in this system.

Wnt3a does not up-regulate the canonical BMP signalling pathway
---------------------------------------------------------------

To identify if Wnt signalling directly increases the BMP ligand, we treated cultured OPC cultures with Wnt3a and looked for changes in BMP4 protein by Western-blot analysis. Wnt3a treatment did not result in an increase in BMP4 protein after 30 min or 3 h, when compared with untreated conditions or BMP4-positive control conditions ([Figure 4A](#F4){ref-type="fig"}). Later time points at 2 and 5 days post-treatment also showed no sign of BMP4 up-regulation (results not shown). To see if Wnt3a could up-regulate the canonical BMP signalling pathway independently from increasing the amount of BMP ligand, we treated cultured OPCs with BMP4 and Wnt3a and looked for increases of phosphorylated-Smad 1/5/8. When cultures were treated with BMP4, there were clear increases in phosphorylated-Smad levels observed by Western blots by 30 min post-treatment ([Figure 4B](#F4){ref-type="fig"}). In contrast, Wnt3a did not noticeably increase Smad levels after the same amount of time. Longer time points, up to 48 h, also did not show increased levels of phosphorylated-Smad (results not shown). These results indicate that Wnt3a does not directly up-regulate canonical BMP signalling.

![Wnt3a does not directly up-regulate the canonical BMP signalling pathway\
Rat cells were treated with Wnt3a or BMP4, cells were harvested for protein at 30 min and 3 h post treatment, and Western blots were performed. (**A**) At both time points, BMP4 bands are visible in the positive control conditions, as compared with untreated and Wnt3a-treated conditions. (**B**) At both time points, phosphorylated-Smad bands are visible in BMP4-treated conditions but not in untreated or Wnt3a-treated conditions. GAPDH was used as a loading control for both analyses.](an003e061f04){#F4}

BMP4 and Wnt3a do not decrease OPC differentiation in a combinatorial manner
----------------------------------------------------------------------------

To determine whether the effects of BMP4 and Wnt3a were additive, we simultaneously treated OPCs with DM containing 50 ng/ml Wnt3a and 10 ng/ml BMP4, both of which separately reduce the number of GalC+ cells by approx. 40% relative to control conditions. We also treated cells with each growth factor individually and with 50 ng/ml BMP4 as a positive control. If BMP and Wnt signalling reduce the percentage of GalC+ cells independently, we could expect to see additional decreases in the number of mature OLs with combined treatment. There were no significant decreases in GalC expression, however, in the combined treatment condition when compared with conditions when either 10 ng/ml BMP4 or 50 ng/ml Wnt3a were added separately ([Figure 5](#F5){ref-type="fig"}).

![Collective treatment with BMP4 and Wnt3a does not inhibit precursor differentiation greater than individual treatment with BMP4 or Wnt3a\
Rat OPCs were cultured and then placed in DM with 50 ng/ml BMP4, 10 ng/ml BMP4, 50 ng/ml Wnt3a or 50 ng/ml Wnt3a and 10 ng/ml BMP4. After 3 days, 50 ng/ml BMP4 decreased GalC+ cells by 92% relative to control conditions (*P*\<0.05), 10 ng/ml BMP4 decreased OPC differentiation by 35% (*P*\<0.05), 50 ng/ml Wnt3a decreased OPC differentiation by 38% (*P*\<0.05) and 50 ng/ml Wnt3a combined with 10 ng/ml BMP4 decreased OPC differentiation by 44% (*P*\<0.05). The difference between the combined addition of BMP4 and Wnt3a was not significantly different from the application of either treatment factor individually (*n* = 3).](an003e061f05){#F5}

To determine what could restrict the effect of Wnt3a to a subset of cells, we labelled OPC cultures with antibody to TCF4, the downstream transcriptional effector of canonical Wnt signalling. Nuclear TCF4 labelling was observed in 46.7% of cultured OPCs ([Figure 6](#F6){ref-type="fig"}), suggesting that it is the nuclear expression of TCF4 that facilitates the effects of Wnt3a on OL differentiation. Taken together, these results are consistent with the interpretation that the same downstream pathway is used by both signalling factors to inhibit OL maturation. It is also consistent with our data that Wnt only affects a subset of TCF4 expressing cells that are targeted in parallel by BMP4.

![TCF4 is expressed in 46.7% of OPCs *in vitro*\
Cultures of OPCs were harvested and grown to confluency, then labelled with antibody to TCF4. Photomicrographs depict a portion of cells co-labelled with DAPI and TCF4, indicating nuclear expression. Arrows indicate examples of double-labelled cells. Quantification of the total number of nuclear expressing TCF cells showed the proportion of positively labelled cells was 0.467±0.071 (*n* = 3).](an003e061f06){#F6}

Wnt3a and BMP4 increase expression of *Id2* mRNA
------------------------------------------------

We used QPCR (quantitative real-time PCR) to determine what downstream effectors are influenced by both Wnt and BMP treatment. OPC cultures were obtained from normal rats as previously described. Cells were grown on 50 mm dishes and treated with Wnt3a or BMP4 for 6 and 48 h. We observed a decrease in *Mbp* transcripts at 48 h after treatment with Wnt3a and BMP4, mirroring our IHC results ([Figure 7A](#F7){ref-type="fig"}). When assaying for *Id2* mRNA, however, both Wnt3a and BMP4 significantly increased transcript levels ([Figure 7B](#F7){ref-type="fig"}). IDs (inhibitor of DNA-binding proteins) are known inhibitors of differentiation, and previous studies have revealed that they are targets of BMP and Wnt signalling ([@B68]; [@B89]). These results indicate that Wnt3a and BMP4 can target the same effectors of OL differentiation.

![BMP4 and Wnt3a regulate *Id2* and *Mbp* transcript levels\
Rat OPCs were cultured and treated with Wnt3a or BMP4 and assayed for QPCR. (**A**) After treatment for 48 h, levels of *Mbp* mRNA were calculated compared with untreated control OPCs. DM-treated cells had a 7-fold increase in *Mbp* expression over that of untreated cells and BMP4-treated cells (*P*\<0.05). This expression was also 2.33-fold more than that of Wnt3a-treated cells (*P*\<0.05, *n* = 4). (**B**) After treatment for 6 h, levels of *Id2* mRNA were calculated compared with untreated control OPCs. BMP4 and Wnt3a treatment increased *Id2* transcript expression 4.7- and 2.2-fold, respectively (*P*\<0.05, *n* = 7).](an003e061f07){#F7}

Wnt3a and BMP4 reduce levels of nuclear Olig2 in OPCs
-----------------------------------------------------

ID2 prevents the nuclear localization of Olig2 after stimulation with BMP4, thus inhibiting BMP signalling ([@B68]). We used IHC to examine the localization of Olig2 after treatment with either BMP4 or Wnt3a. After 2 days of treatment, we observed a significant decrease in the total number of cells in which Olig2 was clearly visible co-localized with cell nuclei in both BMP4- and Wnt3a-treated cultures. There was a 55% reduction in Olig2 and DAPI co-labelling in BMP4-treated cultures and a 19% reduction in Wnt3a-treated cultures relative to controls ([Figures 8A and 8B](#F8){ref-type="fig"}). These results further indicate that BMP4 and Wnt3a are targeting common factors in OPC differentiation.

![BMP4 and Wnt3a decrease levels of Olig2\
Mouse OPCs were cultured, placed in DM, and treated with Wnt3a or BMP4. (**A**) Two days after treatment, cells were labelled for Olig2 and A2B5. (**B**) Bar graphs quantify the number of Olig2+ cells in each condition relative to control. BMP4 decreased the number of nuclei co-labelled with Olig2 by 55% (*P*\<0.01, *n* = 5). Wnt3a decreased the number of nuclei co-labelled with Olig2 by 19% (*P*\<0.05, *n* = 5). Images shown were taken at ×40 magnification.](an003e061f08){#F8}

DISCUSSION
==========

We have analysed the relationship between canonical Wnt and BMP signalling in OL development, and our results indicate that both pathways rely on a fully functional BMP signalling pathway. In primary rodent OPC cultures, BMP4 by itself almost completely eliminates OPC differentiation and significantly increases the number of astrocytes. Wnt3a by itself decreases OPC differentiation by 30--40% without a corresponding increase in astrocyte generation. Blocking the BMP signalling pathway with pharmacological or genetic techniques at different points on the BMP pathway prevents the effects of both BMP4 and Wnt3a. In contrast, blocking the canonical Wnt signalling pathway was able to counter the effect of Wnt3a on OPC differentiation, but not that of BMP4.

To address why Wnt3a only partially inhibits OL differentiation, in comparison with the complete inhibitory activity of BMP4, we examined downstream expression of Wnt effectors. We observed that 46.7% of OPCs in culture express TCF4, which corresponds to the decrease in differentiation after Wnt3a treatment. This suggests two possibilities: TCF4 is expressed only in a subset of OPCs or TCF4 is only transiently expressed in all OPCs and 46.7% of these cells expressed TCF4 at the time of treatment. Both possibilities indicate that the nuclear expression of TCF4 appears to control the ability of Wnt3a to affect OL differentiation. This is consistent with the conclusions drawn by [@B17] concerning TCF4 expression *in vivo*.

To find at what level BMP4 and Wnt3a may be inhibiting OPC differentiation, we performed QPCR and assayed for *Id2* transcript levels. Both BMP4 and Wnt3a consistently reduced transcript levels of *Mbp*, complementing our IHC results, and also increased levels of *Id2*, in keeping with earlier studies ([@B68]; [@B89]). IDs are actively involved in preventing OPC differentiation and OL myelination, largely by preventing nuclear localization of Olig proteins to keep the timing of differentiation precise and regulated ([@B43]; [@B84]; [@B68]; [@B20]; [@B53]; [@B11]). We found that both Wnt3a and BMP4 reduced the number of cells co-labelled with Olig2 in the nucleus, indicating that both factors were actively preventing the nuclear activity and differentiating capabilities of Olig2, possibly via ID2 induction. There was a larger effect of BMP4 treatment on both Olig2 and ID2 treatment when compared with Wnt3a treatment, consistent with our differentiation results.

The BMP and Wnt pathways have many contextually and temporally dependent interactions throughout development ([@B34]). In the developing spinal cord, overexpression of either signalling factor alone induces a dorsalized phenotype, whereas their removal produces ventralized phenotypes, indicating that both signals may have functionally similar, interacting or redundant effects ([@B61]; [@B60]; [@B78]; [@B91]; [@B2]). In some developmental systems, the BMP pathway up-regulates or acts upstream of Wnt signalling, such as in neural crest delamination ([@B7]), keratinocyte development ([@B88]) and dorsal/ventral patterning ([@B91]). Conversely, Wnt signalling can act upstream or up-regulate the BMP pathway, such as during neurogenesis and astrogliogenesis ([@B40]), limb mesenchyme development ([@B27]) and tooth development ([@B49]). The downstream effectors of both signalling pathways can also interact in synergistic manners to regulate transcription ([@B44]; [@B62]; [@B46]; [@B77]; [@B32]), and canonical Wnt signalling can prolong the activity of the BMP pathway ([@B19]). In other contexts, Wnt and BMP signalling can be directly antagonistic, such as in neuroepithelial cell development ([@B33]), aspects of neural development ([@B21]), muscle positioning ([@B5]) and osteoblast development ([@B37], [@B38]; [@B29]). In some systems, such as during aspects of limb bud and apical ectodermal ridge formation, the BMP and Wnt pathways can complexly regulate each other through parallel signalling and feedback systems ([@B76]; [@B82]).

Our results clearly demonstrate that the BMP pathway is essential for the Wnt pathway to inhibit OPC differentiation, as eliminating BMP signalling effectively blocks the effects of Wnt3a. This is not just a result of the BMP antagonist simultaneously blocking Wnt signalling, because genetic removal of BMP receptors also prevented Wnt3a from inhibiting differentiation.

There are three potential mechanisms through which the BMP and Wnt pathways could interact. The most direct identifiable interaction would be through the canonical Wnt signalling pathway up-regulating phosphorylated-Smad, the major effector of canonical BMP signalling. However, we did not detect increases in phosphorylated-Smad levels on Wnt3a treatment, although we were able to consistently detect phosphorylated-Smad increases after standard BMP4 treatment. It is possible that Wnt signalling may directly activate the BMP signalling pathway at levels below detection in Smad assays. We also did not detect up-regulation of BMP protein after Wnt3a treatment using Western-blot analysis.

The second interaction could involve activation of non-canonical BMP pathways, including kinase mTOR (mammalian target of rapamycin)/FRAP via STAT3 (signal transducer and activator of transcription), activated mitogen kinases and LIM kinase ([@B10] for review). In other systems, such as multipotent neural precursor cells, BMP4 activates both canonical and non-canonical pathways for separate effects ([@B66]). It is possible that Wnts and BMPs interact through one of the non-canonical routes. The possibility of signalling through multiple, alternative pathways could also explain why both BMP4 and Wnt3a treatment inhibit OPC differentiation and maintain similar levels of A2B5+ cells, despite only BMP4 directly increasing the number of astrocytes.

Finally, If Wnt signalling does not up-regulate BMP signalling, downstream mechanisms could be evoked. Some common transcriptional targets of both pathways have Smad and TCF/LEF-binding sites in close proximity, indicating that the two pathways have synergistic activity among their downstream effectors, including *Emx2* ([@B77]), *Msx2* ([@B86]; [@B32]), *c-myc* ([@B30]) and *Xtwin* ([@B44]; [@B62]; [@B46]). The BMP and Wnt signalling pathways may also interact during epigenetic regulation of OL differentiation. Recent studies have shown that HDACs (histone deacetylases) compete with activated β-catenin to bind with TCF4. Bound to β-catenin, TCF4 acts as a transcriptional repressor of OL differentiation by up-regulating factors such as ID2/4. Bound to HDACs, TCF4 acts as a transcriptional repressor, inhibiting the activity of ID2/4 and up-regulating myelin-promoting genes such as *Mbp* ([@B52]; [@B74]; [@B26]; [@B89]). Our experiments indicate that canonical Wnt signalling depends on the BMP pathway to inhibit OL development; it is possible that the TCF transcriptional complex requires inherent Smad elements or other downstream effectors of BMP signalling to interact with IDs or other inhibitory elements. The transcriptional activity of the Wnt signalling pathway may then rely on endogenous BMP functioning, and will therefore be inhibited when BMP signalling is abrogated.

Understanding what signals regulate the timing mechanisms of OL maturation will facilitate the development of therapies for myelin disorders. BMP up-regulation has been well documented in many types of CNS disease and demyelinating paradigms ([@B71]). Furthermore, several recent studies demonstrate that Wnt signalling is active during white matter injury as well, including aspects of axonal regeneration ([@B50]; [@B59]), NG2+ cell proliferation ([@B64]; [@B85]) and remyelination ([@B17]). BMPs and Wnts interact in many intricate ways during development, and it is likely that they have similar interactions during CNS injury and recovery. It is, therefore, important to understand how these pathways function independently and in relationship to one another. We have shown that the BMP pathway is a competence factor for canonical Wnt signalling to inhibit OPC differentiation in cell culture paradigms. Further experiments should investigate this interaction during remyelination events and in CNS injury models.
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